Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase? by Takaaki Ono

Get full text

PB1961: INVOLVEMENT OF IMMUNITY IN THE CONTINUATION OF TFR AFTER BOSTINIB DISCONTINUATION by Yuki Fujioka, Takaaki Ono, Naoto Takahashi

Get full text

Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometr... by Yumi Imoto, Yasuaki Mino, Takafumi Naito, Takaaki Ono, Junichi Kawakami

Get full text

Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia by Masamitsu Takaba, Takayuki Iwaki, Tomohiro Arakawa, Takaaki Ono, Yuichiro Maekawa, Kazuo Umemura

Get full text

Comparative study between Helicobacter pylori and host human genetics in the Dominican Republic by Takaaki Ono, Modesto Cruz, José A. Jiménez Abreu, Hiroyuki Nagashima, Phawinee Subsomwong, Celso Hosking, Seiji Shiota, Rumiko Suzuki, Yoshio Yamaoka

Get full text

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase by Ibuki Takatsuka, Hiroya Hirata, Takumi Takahashi, Satoshi Dohtan, Shinichiro Oka, Nami Sakamoto, Masamitsu Takaba, Miwa Adachi, Tomonari Takemura, Yasuyuki Nagata, Takaaki Ono

Get full text